Severe Eosinophilic Asthma Effectively Managed With Benralizumab

This article originally appeared here.
Share this content:
Adverse event rates with benralizumab were not statistically different than with placebo.
Adverse event rates with benralizumab were not statistically different than with placebo.
The following article is part of Pulmonology Advisor's coverage from the CHEST 2018 meeting taking place in San Antonio, Texas. Our staff will report on medical research related to COPD, critical care medicine, and more conducted by experts in the field. Check back regularly for more news from CHEST 2018.

SAN ANTONIO — Patients with eosinophilic severe asthma found that benralizumab significantly improved asthma exacerbation rate, asthma control, asthma-related quality of life, and prebronchodilator forced expiratory volume in 1 second (FEV1), according to the results of a comprehensive systematic review presented at the CHEST Annual Meeting, held October 6-10 in San Antonio, Texas.

Researchers conducted a literature search via PubMed, CENTRAL, CINAHL Plus, EMBASE, IPA, and ClinicalTrials.gov databases for double-blinded, randomized, placebo-controlled, phase 3 clinical trials that measured the effects of benralizumab as add-on treatment in patients with severe eosinophilic asthma. Outcomes of interest were Asthma Control Questionnaire scores, Asthma Quality of Life Questionnaire scores, and prebronchodilator FEV1 values.

Of the 1211 articles that were initial hits in the search, 3 — totaling 2730 participants — met inclusion and exclusion criteria and were included in the analysis. Benralizumab was associated with a significant reduction in annual exacerbation rates. In addition, Asthma Control Questionnaire scores, Quality of Life Questionnaire scores, and FEV1 were significantly improved in patients who received benralizumab. Adverse event rates were not statistically different than with placebo.

“This study provides evidenced-based recommendations for use of benralizumab in asthmatic patients with eosinophilia and [can] help direct current treatment guidelines,” the researchers wrote.

Visit Pulmonology Advisor's conference section for continuous coverage from CHEST 2018

Reference

Mahdavian M, Asghari S. Effects of benralizumab on the management of severe asthma. Presented at: CHEST Annual Meeting 2018; October 6-10, 2018; San Antonio, TX.

You must be a registered member of Clinical Advisor to post a comment.

Sign Up for Free e-newsletters